FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

Roche says the move marks a step forward in its digital transformation strategy

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials

OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

Sudapack breaks ground on major PharmaGuard expansion in Erolzheim

Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production

SAI Parenteral's acquires Australia's Noumed Pharmaceuticals for Rs. 125 Cr

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy